Under 10% of people who could benefit from obesity jabs such as Wegovy are able to get them, warns the World Health Organization as it publishes its inaugural recommendations on the medications.
Considering over a billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be treated with comprehensive and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to widespread availability to the injections that can assist patients in reducing considerable body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even in the current most favorable scenario, the supply of these medications could only cover around 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation urges countries and companies to increase availability, through measures like voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs imitate a body's own hormone to slow digestion, curb appetite and boost the sense of being full so people eat less.
Patients usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Research points to users may see weight return a year later of stopping the medication, because their typical appetite come back.
To be overweight or obese raises your chance for contracting medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the WHO.
